Clinical Study Demonstrates Long Term IOP Reduction With The OMNI® Surgical System Predicate Device (TRAB®360) In Micro-Invasive Glaucoma Surgery

MARCH 14, 2019

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI® Surgical System’s Predicate Devices (TRAB®360) provides a favorable safety profile and substantial long-term reductions in both intraocular pressure (IOP) and IOP-lowering medications. Conducted by Steven Sarkisian, 
+ Read More


Retreatment With A Single TearCare® Treatment Continues To Provide Relief For Patients With Dry Eye Disease

FEBRUARY 12, 2019

A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release.  The TearCare System is indicated for use in meibomian gland dysfunction (MGD), dry eye, and 
+ Read More


Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer

OCTOBER 23, 2018

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has joined the company as Chief Medical Officer (CMO). Dr. Brown is one of the most prolific inventors and innovators in the history of surgical glaucoma.  
+ Read More


Sight Sciences Initiates U.S. Pivotal Trial of the TearCare® System for the Treatment of Dry Eye Disease

APRIL 30, 2018

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the initiation of the OLYMPIA study, a pivotal trial to evaluate the safety and effectiveness of the TearCare® System in patients with dry eye disease. The TearCare® System is the 
+ Read More


Sight Sciences Names Jesse Selnick Chief Financial Officer

MARCH 14, 2018

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the appointment of Jesse Selnick as Chief Financial Officer. Selnick most recently served as Chief Financial Officer and on the Board of Directors of Electric Lightwave, a private equity sponsored 
+ Read More


Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System

JANUARY 04, 2018

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated for the delivery of controlled volumes of viscoelastic fluid as well as the cutting of trabecular meshwork tissue. In addition, the company announced three key 
+ Read More


Sight Sciences Secures $10MM in Oversubscribed Series C Financing

OCTOBER 09, 2017

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with a seasoned ophthalmic industry veteran. Allegro Investment Fund, a privately held fund based in Menlo Park, CA, led the round with full participation 
+ Read More


Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts

FEBRUARY 15, 2017

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs, Ingrid Kane, M.D., Vice President of Global Medical Affairs, Jamie Chakales, Vice President of Global Sales 
+ Read More



Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial

JULY 26, 2016

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT). The VISCO™360 versus SLT Glaucoma Trial is a multi-center, prospective, randomized, controlled clinical evaluation that will study 
+ Read More